Key Takeaways
- Strong Q1, IPO proceeds still idle: Revenue grew on industrial, defense and aerospace strength, while gross margins improved year-on-year. IPO funds concluded only 10 days before quarter-end and remain unutilized.
- Working capital is the headline drag: DIO of 187 days and DSO of ~90 days pushed net working capital to 98 days, but management ties this to customer advances and sees a clear path to 60 days by year-end.
- Order book conversion is the near-term engine: More than half of the ₹2,500 crore order book is executable in the next 12 months, and the total contract value of awards in the pipeline is almost 2x the current order book.
- Margin expansion story is multi-layered: Scale absorption, operational efficiencies and a shift toward build-to-spec programs together offer a 2.5–3.5 point EBITDA upside over a couple of years.
- What to watch next quarter: Whether DIO drops toward the 140-day Q2 target, any new customer logos or program announcements from the significant pipeline, and the pace of IPO fund deployment.
Working Capital & Balance Sheet
- DIO elevated but funded: Inventory days of 187 reflect securing parts ahead of time to lock in revenue, but customer advances rose in parallel, so the net exposure is smaller than the headline number suggests.
- DSO spike is timing, not credit risk: DSO increased to ~90 days because some collections arrived after June 30; management sees no systemic issue or risk with any receivables.
- Net working capital target: Stood at 98 days at quarter-end, with a commitment to bring it down to ~60 days by year-end as supply chains ease and collections normalize.
- Inventory trajectory: DIO expected to fall to ~140 days by end of Q2 and ~120 days by year-end, though supply chain easing is slower than originally anticipated.
- PAT decline explained: Year-on-year PAT fell due to higher finance charges from increased borrowings and interest rates, plus an ₹8 crore unrealized forex gain in the base quarter that did not repeat.
Revenue Mix & End-Market Demand
- Core verticals holding firm: The company operates in aero defense, medical and industrial segments where end demand is not seeing the weakness affecting consumer or automotive sectors.
- Export-led growth trajectory: A good portion of business is for export to Western countries, and exports will continue to make up a greater portion of overall business over the next couple of years.
- India defense is additive, not foundational: While Indian defense offers strong opportunity, management clarified that the company's growth and pipeline are not based on it.
- New customer quality: The new customer added this quarter is an industry leader, comparable in caliber to existing logos, and the win reflects capability-driven diversification into India rather than China-plus-one transfers.
- Seasonality consistent: H1 is expected to contribute ~45% of full-year revenue and H2 ~55%, matching the pattern of the last three years.
Anthony Montalbano: "it really comes down to the type of work we do and the sectors and types of clients we do it. So it's really mission critical, safety critical, electronics manufacturing services primarily focused on aero and defense, medical and industrial segments."
Order Book & Pipeline
- Order book stands at ₹2,500 crore: More than 50% is convertible or executable in the next 12 months, subject to parts availability and customer schedule push-outs.
- Pipeline dwarfs the book: Total contract value of awards being worked on is almost 2x the current order book, though conversion depends on customer-specific practices: some give firm POs, others issue award letters followed by periodic POs.
- Order book growth expected: Management expects growth on a per-year basis but cannot quantify it, given that some orders repeat quarterly and some annually.
Margin Structure & Expansion Path
- Gross margin improved year-on-year: Driven by a better revenue mix and the absence of one-offs that depressed the base quarter last year; full-year gross margins are expected to stay in a range similar to Q1.
- Three levers for EBITDA expansion: Natural margin absorption from scaling plus operational efficiencies can add 1–2 points; build-to-spec programs where the company does design and manufacturing can add another 1–1.5 points.
- Build-to-spec vs build-to-print: In build-to-spec programs, clients engage Cyient DLM on design and manufacturing, giving the company more ownership of the product, more input on design, materials and supply chain control, and higher margins than standard build-to-print work.
- Bottom-line focus over ROCE maximization: Management runs the business for higher margins and bottom-line returns, accepting some trade-off on ROCE, and points to the correlation between bottom-line performance and PE ratios across the EMS industry.
Anthony Montalbano: "So, where we are today as we continue to scale and absorb the costs and along with some operational efficiencies that alone can give us one, two points of opportunity from an EBIDTA perspective and another area of margin expansion for us is really on these build-to-spec program where we do the design and manufacturing... that can give us maybe another point-to-point and a half opportunity there on the overall business."
Business Model & Competitive Positioning
- Pure contract manufacturing, no ODM: The company does not own IP on any current revenue shipped; it is strictly contract manufacturing, with build-to-spec representing the higher-value end of that spectrum.
- PCBA and box build are bundled: These are typically offered together as one business to clients, while cable and wire harnessing is more separate, with expansion expected in complex aerospace harness work.
- Customer advances are negotiation-specific: Not all customers provide advances; they arise when a customer asks the company to order parts ahead of time, triggering a renegotiation of the existing contract. The number fluctuates and should be viewed net of DIO.
- Zero-defect performance: The company received key customer appreciation for achieving literally zero PPM across some aerospace and defense segments.
Capital Allocation & Returns
- IPO funds unutilized: The IPO concluded only 10 days before quarter-end, so proceeds have not yet been deployed.
- PAT set to improve significantly: For the rest of the year, strong operating performance will be aided by lower finance charges as IPO proceeds repay loans, plus higher other income.
- ROCE target of 20–25%: Currently depressed by IPO cash on the balance sheet; management expects to reach the target range over a couple of years.
- Investor day planned: The company intends to host an investor day to showcase manufacturing facilities and capabilities, with details to follow.
Management: "As we have done with Cyient in the past, we will plan to also host an investor day for Cyient DLM Investors show. So, we can actually showcase, and as you know in this case there's a lot more to showcase, our manufacturing facilities and capabilities, and we will keep you posted on that."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Higher than industry average for the year | FY24 |
| EBITDA margin | Similar to last year, 10–11% | FY24 |
| Gross margin | Full-year range similar to Q1 | FY24 |
| DIO reduction | ~140 days by end of Q2, ~120 days by year-end | Q2 FY24 / FY24 exit |
| Net working capital | ~60 days by year-end | FY24 exit |
| PAT | Significant increase for rest of year, aided by lower finance charges and higher other income | FY24 |
| Order book conversion | More than 50% of ₹2,500 crore order book executable | Next 12 months |
| ROCE | 20–25% range | Over a couple of years |
| H1/H2 seasonality | H1 ~45%, H2 ~55% of full-year revenue | FY24 |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue | ₹217.1 cr, +27.6% YoY |
| EBITDA | ₹20 cr, +72.6% YoY |
| EBITDA margin | 9.2%, up 243 bps YoY |
| PAT | 126 bps lower YoY, due to higher finance charges and absence of one-off forex gains in base quarter |
| Gross margin | Significantly higher YoY, driven by better revenue mix and one-offs in Q1 last year |
| Order backlog | ₹2,499.7 cr, +89% YoY |
| Order intake during quarter | ₹3.36 cr |
| Revenue mix: Aerospace & Defense | 56% of revenue |
| Revenue mix: Industrial | 30% of revenue |
| Revenue mix: Med-tech | 10% of revenue |
| Revenue mix: Others (primarily rail) | 4% of revenue |
| Export share | ~70% of revenue, domestic 30% |
| DIO (inventory days) | 187 days, expected to reduce to 140 days by Q2 and 120 days by year-end |
| DSO (receivables days) | ~90 days, elevated due to collections received post quarter-end |
| Net working capital days | 98 days, target of 60 days by year-end |
| Pipeline | Over ₹70 cr, backed by major aerospace and defense clients |
| ROCE target | 20% to 25%, expected to take a couple of years to achieve |